PDS Biotechnology to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 13 2021 - 8:30AM
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing novel cancer therapies based on
the Company’s proprietary Versamune® T-cell activating technology,
announced today that its management will present at the Oppenheimer
Fall Healthcare Life Sciences & MedTech Summit.
The presentation will provide an update on the three ongoing
PDS0101 Phase 2 clinical trials. The talk will also provide updates
on progression of two other investigational pipeline products
PDS0102 (Versamune®-TARP) and PDS0103 (Versamune®-MUC1) into human
clinical trials. The conference is taking place virtually from
September 21 - 23, 2021. Details for the presentation are as
follows:
Oppenheimer Fall Healthcare Life Sciences & Med Tech
Summit:Date: Tuesday, September 21, 2021Time: 3:45 pm
EDTInvestors can register for the conference HERE.
Following the conference a webcast replay of the presentation
will be available on the Investor section of the company’s website,
https://pdsbiotech.com/.
About PDS BiotechnologyPDS Biotech is a
clinical-stage immunotherapy company developing a growing pipeline
of cancer immunotherapies based on the Company’s proprietary
Versamune® T-cell activating technology platform. Our
Versamune®-based products have demonstrated the potential to
overcome the limitations of current immunotherapy by inducing in
vivo, large quantities of high-quality, highly potent
polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells.
PDS Biotech has developed multiple therapies, based on combinations
of Versamune® and disease-specific antigens, designed to train the
immune system to better recognize diseased cells and effectively
attack and destroy them. The company’s pipeline products
address various cancers including breast, colon, lung, prostate and
ovarian cancers. To learn more, please visit
www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
About PDS0101PDS Biotech’s lead candidate,
PDS0101, combines the utility of the Versamune® platform with
targeted antigens in HPV-expressing cancers. In partnership
with Merck & Co., PDS Biotech is evaluating a combination of
PDS0101 and KEYTRUDA® in a Phase 2 study in first-line treatment of
recurrent or metastatic head and neck cancer. PDS Biotech is also
conducting two additional Phase 2 studies in advanced
HPV-associated cancers and advanced localized cervical cancer with
the National Cancer Institute (NCI) and The University of Texas MD
Anderson Cancer Center, respectively.
Media & Investor Relations Contact:Deanne
RandolphPDS BiotechPhone: +1 (908) 517-3613Email:
drandolph@pdsbiotech.com
Rich CockrellCG CapitalPhone: +1 (404)
736-3838 Email: pdsb@cg.capital
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Mar 2024 to Apr 2024
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Apr 2023 to Apr 2024